"pRNFL and GCIPL were shown to be robust markers of neuroaxonal damage of the visual pathway throughout the disease course in both relapsing and progressive [#MultipleSclerosis]. However, longitudinal assessment of #retinal thickness as currently performed in clinical routine, are subject to a considerable amount of measurement variability and may therefore not be suitable markers of progression on a single patient level."
Professor of Neurology at University of Antwerp with a passion for MS and rare CNS neuroimmune disorders || Senior Neurologist at Antwerp University Hospital
Very interesting study in Nature Communications on the use of OCT in MS patients. Decreased values reflect neurodegeneration and are predictive at the group level, but longitudinal change rates were subject to high measurement variability. Remains to be investigated what OCT measurement adds to MRI monitoring in MS. In conclusion: "Using the current state of technology, longitudinal assessments of retinal thickness may not be suitable on a single patient level." The quest for individual patient level prognostic biomarkers in MS remains.
